In ₹ Crore except Per Share Latest Annual	AMRUTANJAN FY26	FERMENTA no data	JAGSNPHARM FY26	NGLFINE FY26	Peer Average
Valuation — at last close
P/E	◆ 24.61×	—	36.09×	33.51×	34.80× -29%
P/B	◆ 3.85×	—	5.60×	4.90×	5.25× -27%
EV/EBITDA	◆ 18.35×	—	24.80×	23.07×	23.94× -23%
Market Cap	₹1,425 Cr	—	₹1,547 Cr	₹1,613 Cr	₹1,580 Cr -10%
Growth
Revenue CAGR 3Y	9.80%	—	6.66%	◆ 21.68%	14.17% -31%
Revenue CAGR 5Y	◆ 13.96%	—	8.85%	—	8.85% +58%
Net Income CAGR 3Y	13.29%	—	17.26%	◆ 32.91%	25.09% -47%
Revenue YoY (latest Q)	9.49%	—	9.28%	◆ 33.57%	21.43% -56%
Net Income YoY (latest Q)	-47.47%	—	0.13%	◆ 99.09%	49.61% -196%
Profitability
EBITDA Margin	15.06%	—	◆ 20.22%	14.51%	17.36% -13%
Net Income Margin	11.52%	—	◆ 15.00%	9.61%	12.30% -6%
Return on Common Equity	16.62%	—	◆ 16.69%	15.74%	16.21% +2%
Return on Capital Employed	◆ 19.28%	—	17.99%	14.96%	16.48% +17%
Return on Assets	12.45%	—	◆ 14.48%	9.83%	12.16% +2%
Credit & Quality
Total Debt/Equity	◆ 0.00×	—	0.00×	0.33×	0.17× -100%
Interest Coverage	◆ 355.72×	—	47.31×	11.89×	29.60× +1102%
Scale — latest FY
Revenue / Total Income	₹503 Cr	—	₹287 Cr	₹501 Cr	₹394 Cr +28%
Net Income	₹57.9 Cr	—	₹43.1 Cr	₹48.1 Cr	₹45.6 Cr +27%
Total Assets	₹509 Cr	—	₹317 Cr	₹545 Cr	₹431 Cr +18%
EPS	₹20.03	—	₹6.4	₹77.9	₹42.15 -52%
Book Value per Share	₹128.06	—	₹41.24	₹532.91	₹287.08 -55%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.